Thursday, July 29, 2021

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hails Successful Testing for Effective Transformation of Antivirals for Greater Bioavailability

  • Lexaria Bioscience is a drug delivery technology developer advancing its IP for transforming existing consumer products and medications that may improve their availability and bioavailability
  • The analysis of Lexaria’s DehydraTECH(TM) shows it did not create unwanted new molecular entities during the transformation process, did not inhibit the drugs’ expected antiviral functions and did increase absorption
  • The DehydraTECH testing has been in conjunction with drugs used to treat SARS-CoV-2/COVID-19, HIV/AIDS and hepatitis, although the company envisions its technology becoming responsive to a much wider array of viral illnesses
  • The company envisions building on its recent successes with larger studies of the DehydraTECH process in animals infected with viruses such as SARS-CoV-2/COVID-19 or HIV/AIDS and hopes to eventually form partnerships with established pharmaceutical giants

Oral drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX)provided investors an update July 22 on the success of its efforts to advance its proprietary technology toward scalable commercial use for improving the treatment of select viral illnesses. 

Lexaria has met three primary objectives in its investigation of antiviral drug conversion process outcomes as the antiviral drugs are processed with Lexaria’s patented DehydraTECH, according to the company’s news release (https://nnw.fm/Anr4G).

Lexaria aims to make drugs more bioavailable through DehydraTECH conversion without impairing the drugs’ essential functions. Many antiviral drugs currently available experience a decrease in bioavailability when taken orally because of poor intestinal uptake and/or significant liver biotransformation within the patients’ bodies — the company cites the anti-inflammatory drug colchicine, which has a bioavailability of about 45 percent and a narrow margin between what is regarded as safe and toxic dosing. 

Lexaria’s three primary objectives in testing DehydraTECH’s processing of colchicine and four other anti-inflammatories — darunavir, ebastine, efavirenz and remdesivir — were to determine if DehydraTECH processing would demonstrate evidence of increasing absorption through oral delivery, evidence that the drug compounds would continue to inhibit viruses as expected in mammalian cells, and evidence that the processing would not lead to the creation of new molecular entities (“NMEs”) requiring new regulatory approvals. 

The success achieved during the company’s testing paves the way for larger analysis of the DehydraTECH-processed drugs in vivo in animals infected with SARS-CoV-2/COVD-19, HIV/AIDS or other infectious disease-causing viruses, according to the company, with the ultimate aim of forming partnerships with established pharmaceutical industry drug-makers who may be interested in incorporating DehydraTECH technology with those tested drugs, or other drugs with similar characteristics. 

The five drugs being analyzed in conjunction with DehydraTECH processing are representative of protease inhibitors (“PIs”), reverse transcriptase inhibitors (“RTIs”) and a tubulin polymerization and microtubule inhibitor (“TPMI”) used to treat HIV, hepatitis C, hepatitis B, COVID-19 infections and cancers. Lexaria hopes to apply its discoveries to pharmaceuticals that fight other virus-triggered diseases such as shingles, influenza and viral forms of gastroenteritis, hepatitis, meningitis, and pneumonia. 

The company’s news release cites statistics noting that 37.7 million people are currently known to be infected with HIV and 36.3 million people have died from HIV/AIDS since the beginning of the epidemic, between 290,000 and 650,000 people die every year from virus-driven seasonal influenza, and over 189 million people have been infected by SARS-CoV-2 in the current global epidemic with more than 4 million of them killed by the illness. 

Vaccines have helped reduce the incidence and mortality of these viral illnesses, but effective oral delivery has the potential to increase the availability of medications where vaccines cannot be widely administered. Additionally, in each of the antiviral drug classes currently being tested, the outcomes in animals have demonstrated up to a three-fold increase in bioavailability to the bloodstream over established methods, which may ultimately prove a means of reducing the costs of administration.

“We are looking at repurposing some of these drugs, being able to take an antiviral drug that traditionally could only be administered, for example, by injection. We might be able to apply it in an oral form through a pill,” Lexaria CEO Chris Bunka told Investing News Network in a June report (https://nnw.fm/NrPw9). “Our delivery from oral to the bloodstream is as little as two minutes. We’re outrageously fast for oral technology,” Bunka stated. 

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Proprietary Imaging System Set to Advance Bladder Cancer Visualization

  • Approximatively 75-85% of patients with confirmed cases of bladder cancer are diagnosed with non-muscle invasive (“NMIBC”)
  • Imagin Medical’s innovative technology is targeting this type of bladder cancer and set to be completed in 2022 
  • Blue light cystoscopy helps surgeons visualize the cancerous cells that are not detected by white light, enabling an improved resection

Non-muscle-invasive bladder cancer (“NMIBC”) is a type of bladder cancer that has not infiltrated the other muscle tissues inside the bladder or spread to the lymph nodes. Approximately 75-85% of patients presenting with bladder cancer are diagnosed with NMIBC. The most common symptoms of NMIBC which may prompt initial testing is blood in the urine (https://nnw.fm/86isJ).

The primary procedure used to detect bladder cancer is called a cystoscopy, which uses an endoscope and, typically, white light visualization. White light cystoscopy has been the standard for more than 90% of the procedures for decades and is beneficial in removing cancerous growths that protrude from the bladder wall. Yet, it is almost impossible to detect and resect cancerous cells that lay flat against the bladder, leaving some cells behind and causing a higher risk of recurrence. Approximately 50% of patients who have had a cystoscopy to remove NMIBC see their cancer return. Right now, approximately 724,000 people are living in fear that their bladder cancer will come back (https://nnw.fm/uKT19).

Blue Light Cystoscopy (“BLC”), used with and FDA approved imaging agent that fluoresces the cancer cells, was introduced in 2010.  Although proven to be more effective in identifying cancerous cells and reducing recurrence, blue light is still only used in approximately 10% of bladder cancer procedures due to training, cost and ease-of-use issues. 

To address these issues,  Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed the i/Blue Imaging System(TM), an innovative technology designed to significantly improve the way surgeons visualize cancerous cells for more accurate bladder resection. This patented technology allows for white and blue light images to be projected side-by-side simultaneously, enabling better surgical technique. The i/Blue System will attach to most endoscopes currently on the market, protecting hospitals’ investment in instruments they already own and enabling their adoption of blue light cystoscopy at a significant cost savings.  

Imagin Medical’s technology has entered the manufacturing stage with the company’s partner, Lighthouse Imaging, an FDA-registered and ISO 13485:2016 certified manufacturer. The i/Blue Imaging System is expected to be completed in 2022. 

With the i/Blue Imaging System, Imagin Medical is poised to establish a new standard in bladder cancer visualization by radically changing how cystoscopies are performed and ultimately helping improve patients’ lives and long-term outlook. Imagin Medical’s target is estimated to be a $400M portion of the global endoscopy market valued at $25.59 billion in 2019 and is expected to grow at a CAGR of 6.6 percent to reach a total estimated value of $35.23 billion by 2024 (https://nnw.fm/7Fbxl). 

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://nnw.fm/IMEXF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Green Hygienics Holdings Inc. (GRYN) to Become First Hemp Company to Develop ESG Report Using SASB Framework

  • The company plans to incorporate systemic environmental, social, and governance (“ESG”) factors into business planning and investment decision-making
  • The initial Sustainability Accounting Standards Board (“SASB”) report has been completed, and sustainability consulting firm KERMIDA Inc. is currently organizing the data compiled by Green Hygienics
  • An ESG program can significantly benefit companies in the industry, from drawing in more investors to winning new business, gaining better talent and improving media coverage
  • The industrial hemp market size is expected to reach $15.26 billion by 2027 due to the rising demand for food, supplements, cosmetics, and personal care items

Green Hygienics Holdings (OTCQB: GRYN), a California-based innovative and tech-based enterprise that is focused on the high cultivation standards, processing, and manufacturing of industrial hemp for pharmaceutical-grade bioactive cannabinoids, is enhancing its corporate responsibility and sustainability goals to empower environmental progress. The company plans to incorporate systemic environmental, social, and governance (“ESG”) factors into business planning and investment decision-making.

With the help of KERAMIDA Inc., a premier sustainability consulting firm, Green Hygienics is developing a Sustainability and ESG report using the Sustainability Accounting Standards Board (“SASB”) framework, maintained by the Value Reporting Foundation. Sustainability and ESG are an integral part of the Company’s value system and are committed to driving sustainability by becoming a more effective corporate citizen.

Green Hygienics is the first industrial hemp company to undertake a Sustainability and ESG report. The company is getting ahead of the government’s push to require ESG metrics measurement and reporting. Investors are also pressuring companies to measure, benchmark, and report ESG metrics. These investors pay a premium on companies that develop strong ESG policies. These are the companies that are seeing better valuations and market performance.

According to a Hemp Industry Daily report, companies of all sizes in the industry can realize significant benefits from developing a corporate responsibility program, including (https://nnw.fm/VUYTz):

  • Winning new business and increasing customer retention
  • Attracting talent and maintaining an exuberant workforce
  • Positive media
  • Differentiation from competitors
  • Saving money on energy and operating costs

ESG goals are achievable by any firm by breaking down the concept into different components:

  • Environmental impact – covering everything from a company’s greenhouse gas emissions to resource depletion, nature conservation, waste, and pollution.
  • Social impact – including a firm’s working conditions, employee relations, health, and safety. It also includes a firm’s interaction with local and indigenous communities.
  • Governance – consisting of the structures within a company, like the board of directors, diversity, pay equity, political lobbying, tax strategy, supply chain policies, and executive pay.

ESG is the measurement of all these different aspects, benchmarking them, and reporting them.

Green Hygienics is positioned to deliver a secure supply chain solution and product efficacy to a range of industry customers and leverage the strategic advantages within its own consumer brand portfolio, securing a strong position in the expanding hemp market. The size of the industrial hemp sector is expected to reach $15.26 billion by 2027, expanding at a CAGR of 15.8% over the forecast period. In North America, the market is expected to expand by a CAGR of 20.4% from 2020 to 2027 due to the rising demand for food, supplements, cosmetics, and personal care items (https://nnw.fm/q2J4O).

Developing an ESG program is likely to further cement Green Hygienics’ position in the market, as well as influence positive investor interest and growth opportunities. The company has already finished its SASB Report process and is now interviewing and collecting data from utilities, while also organizing the related data for the KERMIDA Inc. team. Green Hygienics hopes to create the final ESG report in about a month.

For more information, visit the company’s website at www.GreenHygienics.com.

NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://nnw.fm/GRYN

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

What a Post-Pandemic Advertising Market Looks Like

NetworkNewsWire Editorial Coverage: From Main Street to Wall Street, the COVID-19 pandemic shook up the world, and the reverberations are still echoing. High-flying growth stocks related to software and cloud communications have cooled down since late in 2020 as people return to offices and unlock houses to go outside again. Sure, there is still talk about delta and other variants of SARS-CoV-2 wreaking havoc, but market participants are now also talking about what a post-coronavirus world is going to look like. Certain markets — the hospitality sector for instance — will steadily return to normal after more than a year of lockdowns. Others, such as media spending, will never be the same. Trends away from television and radio toward digital channels have accelerated and quite likely will experience a boon in the coming months and years as ad budgets increase will full economic reopenings. As advertisers look for solutions, they will continue to turn to social media influencers and content creators as sophisticated strategies to sway consumers toward their products and services. That’s right in the wheelhouse of Clubhouse Media Group Inc. (OTC: CMGR) (Profile), a company aggregating an impressive portfolio of influencers and content creators from sports stars and entertainers to niche experts that have the ear of millions of followers and the platform technology to effectively target any demographic. Coming out the other side of the pandemic, top companies like the Trade Desk Inc. (NASDAQ: TTD), Magnite Inc. (NASDAQ: MGNI), ViacomCBS Inc. (NASDAQ: VIAC) and Roku Inc. (NASDAQ: ROKU) are knee deep in the advertising evolution, making adaptations that will continue to see the companies thrive going forward.

  • eMarketer forecasts $455.3 billion in global digital ad spending in 2021, up 20% from 2020 with a bias towards display spending over search.
  • Clubhouse Media Group has 200-plus content creators across four professionally run content houses and a network that reaches more than 400 million followers.
  • CMGR also offers proprietary Magiclytics software, a robust platform for analyzing social media campaign effectiveness.
  • Clubhouse just inked a joint services agreement with Rick Ware Racing, an American motorsports team that competes in the NASCAR.

$455 Billion in Digital Ad Spending

During the pandemic, people were forced into digital channels to shop, work, communicate and entertain. Advertisers know this and believe that many will maintain the digital lifestyle now that it’s part of their life as evidence by eMarketer forecasting total digital ad spending of $455.30 billion in 2021. That’s up about 20% from 2020, but a look under the hood shows that analysts are calling for 55.2% of the total spend to go to display advertising compared to 40.2% for search, widening the gap between the two by 5 percentage points, or $68.12 billion in dollars, from 2020.

Hungry for meaningful return on investment, advertisers are increasingly looking to the emerging market of social media influencers and content creators in combination with next-generations machine learning and artificial-intelligence technologies for the results they desire. Armed with these types of marketing tools, a juggernaut such as Nike can reach its global target audience as easily and precisely as a homemade, gluten-free cookie maker in southeastern Ohio can hit its target in Athens. Results that both are willing to pay for, as noted by a Business Insider market report estimating companies will spend up to $15 billion on influencer marketing in 2022, pushing it passed parity with local TV ad revenue.

Clubhouse Media Group Inc. (OTC: CMGR) is in front of the trend, already building a global network of four professionally run content houses, with each hosting in excess of 50 content creators. All four content houses have their own brand, group of influencers and production capacities to keep cranking out content to entertain and inform followers. Clubhouses’ portfolio of services available to those handpicked influencers include management, production and deal-making. The business model is designed for Clubhouse to reach out in all directions, not only offering services to corporate customers but also via management services to individual influencer clients, as well as operating an investment business specializing in M&A or investments directly related to social media markets.

CMGR’s flagship content house is emblematic of the brand. Clubhouse Beverly Hills operates from a massive 12,000-square-foot, seven-bedroom, nine-bathroom, $23-plus million gated house in the glamorous 90210 zip code. A complete production team and chosen group of content creators live in the house, constantly collaborating and producing content that is pushed out through all the group’s social media channels. Other Clubhouse content houses include Clubhouse Europe, located on the island of Malta in the Mediterranean; DanceDome LA, which includes a custom dance studio; Society Las Vegas, located just 10 minutes from the world-famous Las Vegas Strip; and Dobre House, the newest clubhouse, also located in Beverly Hills.

With content houses of this caliber and content creators such as Indy car superstar Lindsay Brewer as part of the team, the reach is expansive. The network has more than 400 million followers in total and has delivered more than 1.5 billion monthly social impressions. The company defines its total followers as a sum of all followers across all social platforms, inclusive of Clubhouse influencers and corporate-owned social media accounts. TikTok’s video platform is the single biggest driver of followers for the group at roughly 290 million, followed by 51.7 million on Instagram, 56 million on YouTube, 2.6 million on Snapchat and 2 million on Twitter.

The Magic Behind Clubhouse Analytics

Clubhouse’s revenue model is circular. The company generates cash flow by claiming a piece of any deal related to content of its affiliated creators (contracted content or sale of proprietary content) and through providing data analytics from its package of tools branded Magiclytics. Through acquisition and in-house development, Clubhouse has created Magiclytics as a software platform enabling brands to monetize influencer marketing more efficiently by analyzing campaigns, optimizing budgets and succinctly selecting social media influencers best for any given job.

Coupling machine learning and artificial intelligence with other types of data (i.e., historical, campaigns, etc.), Magiclytics accurately provides insights about how brands should spend marketing dollars. Again, the model is circular in that a brand can come to Clubhouse looking for campaign management, influencers and analytics, or a Clubhouse-affiliated influencer can take the data to a brand to demonstrate why they are a perfect fit to advertise for their brand. Either way, Clubhouse makes money.

Product Launch on Tap

Clubhouse has an advisory board that is an anomaly for an OTC-listed company. With members that include a partner from venture capital fund A16Z (Andreessen Horowitz) and a leading media executive who previously held the positions of GM at PBS, managing director at BBC Worldwide America, president of Viacom Productions, and executive vice president of Primetime at NBC Entertainment, the company is not sitting still. CMGR intends to launch products under its own brand and use its stars and network power for viral advertising. With an army 400 million strong, influencers such as Lindsay Brewer, professional wrestler Taynara Conti, the Dobre Brothers, and more, the Clubhouse stable can get the word out quickly.

This is tearing a page right from the game plan of similar key influencer networks such as Kylie Jenner and Kim Kardashian, both of whom grew their brand’s valuations to unicorn status ($1 billion+). In 2019, Jenner sold a majority stake of Kylie Cosmetics to beauty firm Coty for $600 million. Kardashian followed that by selling 20% of her KKW Beauty to Coty for $200 million in January.

Racing Sweet Spot

Brewer, who has been coined the Future of IndyCar, was just joined by another household racing name in Clubhouse’s garage. Earlier this month, Clubhouse inked a joint services agreement with Rick Ware Racing (RWR), an American motorsports team that competes in the NASCAR Cup Series, NASCAR Xfinity Series, WeatherTech SportsCar Championship, NTT IndyCar Series, and IMSA Sports Car Championship Series. The pact with RWR also includes a new relationship with Fintekk, a motorsports racing and marketing company already working with RWR.

The new agreement is beneficial to all from the top-down. Each company will bring its social media and marketing teams to the table for collaboration to promote each other’s brands throughout the term of the contract. For providing its comprehensive network to RWR, Clubhouse will get prominent logo placement on RWR vehicles during all 11 events its team races in both IndyCar and NASCAR circuits through September 26, 2021. This includes those of Formula One/IndyCar legend Romain Grosjean and IMSA Asia Le Mans champion Cody Ware and others in the RWR lineup.

Adapting and Thriving

Today’s consumer is savvier than ever. The days of blasting consumers with digital pop-up ads are over; technology can filter it out or the user will simply close the tab annoyed. Banner ads are glossed over as if nonexistent. Television ads are skidding because of cord cutting, and DVRs make it possible to fast-forward through commercials. Indeed, the market is dynamic, and if brands and providers want to be at the top of their game, they must adopt next-generation technologies or potentially sacrifice share in the lucrative $150-billion global advertising industry.

The Trade Desk Inc. (NASDAQ: TTD), a global adtech leader, has recently launched Solimar, its new trading platform designed to help marketers optimize their digital advertising campaigns across the open internet. More than two years in the making, Trade Desk’s bespoke platform was a response to the rapidly evolving digital-marketing environment wherein clients can capitalize on their first-party data for greater precision while advancing consumer-conscious privacy in a cross-channel digital media environment including CTV (connected TV).

Magnite Inc. (NASDAQ: MGNI) operates the world’s biggest independent sell-side advertising platform. The company’s  platform enables publishers to monetize various screens and formats, including CTV, desktop display, video, audio, and mobile, as well as allows agencies and brands to access brand-safe ad inventory and execute advertising transactions. Adding to its offerings, Magnite just acquired SpringServe, a leading ad-serving platform for CTV that manages multiple aspects of video advertising for CTV publishers, includin such as inventory routing, customized ad experiences, and advanced podding logic, for $31 million.

ViacomCBS Inc. (NASDAQ: VIAC) is an iconic global media and entertainment company that creates premium content within its portfolio of consumer brands such CBS, Showtime Networks, Paramount Pictures, Nickelodeon, MTV, Comedy Central, BET, Paramount+, Pluto TV and Simon & Schuster, among others. In addition to offering innovative streaming services and digital video products, ViacomCBS provides powerful capabilities in production, distribution and advertising solutions, meaning it stays on top of trends.

Roku Inc. (NASDAQ: ROKU), a vendor of streaming hardware, software and services, saw a boon during the pandemic lockdowns, as measured by gains in both user base and engagement. Revenue from Roku’s platform unit, which includes its ad busines and media sales, during the first quarter of 2021 spiked 101% to $466.5 million, as streaming hours increased by 1.4 billion hours over last quarter to 18.3 billion.

The advertising space has always been extremely competitive, with content serving as king to attract viewers. In days gone by, the content may have been a newspaper article, a radio show or television program, but things have changed. Those pieces of content still have their places in monetizing from ads, but they are gradually seeing their importance being shared with the power of social media content and influencers to best target potential consumers. All that COVID did was put pressure on the gas pedal to accelerate an already inevitable trend.

For more information about Clubhouse Media Group, please visit Clubhouse Media Group Inc.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Companies Smashing the Psychedelic Ceiling

NetworkNewsWire Editorial Coverage: It’s early on in a burgeoning market, but there is certainly reason to be optimistic about the future of psychedelic medicines as a promising treatment for a broad spectrum of diseases and conditions. In fact, some breakthroughs may be closer than initially anticipated. After decades of stigma from their recreational use, psychedelics are now gaining momentum for medical applications as the U.S. Food and Drug Administration has signaled its intent to evaluate the compounds based on the merit of their clinical efficacy. The range of target indications is widening, the number of studies for different types of psychedelics is growing and specialized clinics are cropping up, a trio of signals that approved medical applications of psychedelics may be here before long. The diversity of approaches makes the market particularly interesting for psychedelic market participants. For instance, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (Profile) is studying how its novel technologies address chronic pain and eating disorders — two areas that have been particularly elusive for traditional drug makers. Seelos Therapeutics Inc. (NASDAQ: SEEL) is looking at a new spin on ketamine for certain types of depression, while Awakn Life Sciences Corp. (NEO: AWKN) and Field Trip Health Ltd. (TSX: FTRP) (OTCQX: FTRPF) are in the clinics and R&D businesses, and Small Pharma Inc. (TSX.V: DMT) is evaluating other psychedelics for depression.

  • Most psychedelic drug developers are working on drugs for mental illness, particularly depression; Tryp is targeting chronic pain and eating disorders.
  • Tryp Therapeutics is advancing novel drug candidates made from psilocybin, the psychedelic component found in magic mushrooms.
  • Tryp expects to submit two separate INDs this year for upcoming Phase 2a clinical trials.
  • Only an elite group of companies have initiated Phase 2 clinical trials exploring psychedelic-related compounds; those companies’ valuation ranges from $85 million to $2.5 billion versus Tryp’s $31 million.

Psychedelic Catalysts

Psychedelics reached an inflection point in 2018 when the FDA tagged psilocybin, the hallucinogenic compound found in “magic” mushrooms, with a Breakthrough Therapy designation to treat depression in patients who didn’t meaningfully respond to two different types of antidepressant therapies. The vaunted designation is a priority review pathway reserved for new drugs believed to offer a substantial improvement over anything on the market today. The designation lent a great deal of credence to a compound still categorized as a Schedule I drug under the Controlled Substance Act, a categorization that restricts the use of the compound and criminalizes its possession outside of medical applications.  A second Breakthrough Therapy designation followed in November 2019 for the treatment of major depressive disorder.

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is optimistic that psilocybin can be beneficial in other large markets where patients and doctors alike are eager to see alternatives to the lackluster drugs available today. Headquartered in San Diego, California, Tryp has assembled a team of veritable experts in its C-suite and scientific advisory board, which is chaired by Dr. Robin Carhart-Harris, one of the world’s leading minds in psychedelic medicines. Dr. Carhart-Harris also serves as director of the Neuroscape Psychedelic Division at the University of California, San Francisco as well as founder and head of the Centre for Psychedelic Research, Division of Brain Sciences, at Imperial College London where his work was part of which supported the first Breakthrough Therapy designation for psilocybin.

Tryp’s TRP-8802 and TRP-8803 are the flagship products of the company’s Psilocybin-for-Neuropsychiatric Disorders, or PFN program. TRP-8802, a standard oral form of synthetic psilocybin, is being developed for several different indications, including chronic pain (more specifically, fibromyalgia) and eating disorders. TRP-8803 is a patent-pending psilocybin-based product being developed by Tryp with a unique formulation and novel route of administration. The expectation is that TRP-8803 will be able to improve the experience for patients receiving psychedelic therapies versus that of conventional oral administration. Tryp will be using TRP-8802 for its Phase 2a clinical trials and expects to use TRP-8803 for Phase 2b studies and beyond.

The development strategy involves leveraging the known safety and pharmacokinetic profiles of psilocybin to jump right into Phase 2a trials — a stage of studies that aims to demonstrate the efficacy of psilocybin for the targeted indications. To do so, Tryp has teamed up with leading companies whose expertise will be invaluable in its development. Curia (formerly AMRI) is manufacturing the active pharmaceutical ingredient (“API”) for the synthetic psilocybin that is the basis for the PFN program. Alcami will develop the analytical methods and final drug products. Fluence is handling the psychotherapy designs for the trials. Clinlogix has been retained as the Contract Research Organization (“CRO”) for the planned Phase 2a studies. Furthermore, Tryp is partnering with world-leading academic institutions to conduct the trials: the Chronic Pain & Fatigue Research Center at the University of Michigan for fibromyalgia and the University of Florida for eating disorders.

Time for New Pain Relief

As companies position themselves for different indications with different compounds, Tryp is a first mover with plenty of runway to pull away in the areas of chronic pain and certain eating disorders. Within the chronic pain category, Tryp has its sights initially set on fibromyalgia, a common (~4 million U.S. patients), complex disease characterized by widespread musculoskeletal pain, fatigue, body tenderness, memory problems and sleep disorders. A true pioneer, Tryp has partnered with the University of Michigan to lead the world’s first Phase 2 clinical trial for a chronic pain indication using a psychedelic compound.

The source of fibromyalgia is not known, but one commonly accepted overarching thesis is that people with the condition process pain differently. Without addressing the source, painkillers are commonly prescribed, but only mask the pain. Unfortunately, that puts fibromyalgia patients at risk of opioid addiction and falling into an opioid epidemic that claims more than 50,000 American lives by overdose annually. Looking at the stats shows how badly this market needs safer alternatives. Approximately 30% of fibromyalgia patients (~1.2 million Americans) are prescribed opioids for their pain. After a year of therapy, owing to ineffectiveness and unpleasant side effects, only about 10% are following their physician’s care plan.

Tryp intends to have an Investigational New Drug (“IND”) application filed with the FDA this quarter for the upcoming Phase 2a trial with the University of Michigan. The university will also conduct research to advance the development of TRP-8803 for the purpose of expanding Tryp’s patent portfolio and for use of TRP-8803 in Phase 2b and subsequent trials.

Disrupting Eating Disorders

With eating disorders affecting an estimated 9% of the world’s population, including nearly 29 million Americans, it’s a significant market opportunity. However, traditional biotechs and pharmaceutical companies can claim minimal success at best in conquering eating disorders. When it comes to binge eating disorder (“BED”), a primary target of Tryp, Vyvance, an ADHD drug by Shire with an expanded indication approved in 2015, is the only drug on the market specific to the disease.

Tryp plans to have an IND application submitted to the FDA for a Phase 2a trial evaluating TRP-8802 in patients with BED and hypothalamic obesity. The University of Florida’s Dr. Jennifer Miller is serving as the principal investigator in the trial. Miller is world-renowned for her expertise in eating disorders and has affirmed that patients face a dearth of treatment options to help with their afflictions.

Markets Reward Phase 2

Tryp is one of an elite group to reach Phase 2 research with a psychedelic drug compound, so initiating multiple Phase 2a trials this year represents a major milestone. Early-stage drug developers are typically valued based on advancing drug candidates towards commercialization since revenue and earnings are absent. With each completed phase in the FDA process, risk of failure is reduced, odds of an FDA approval are increased, and market value rises appropriately. When it comes to mid-stage studies, valuation have been shown to increase fourfold upon successfully completing Phase 2 clinical trials.

To date, seven public companies have initiated Phase 2 studies for a psychedelic-based therapy. The majority are targeting depression, which is not surprising given the library of anecdotal and clinical research supporting the potential to make an impact where conventional drugs have mostly failed. For those companies making the list, there is a wide range of market valuations, ranging from $85 million to $2.5 billion. As it looks to commence Phase 2 trials, Tryp has a market capitalization of approximately $31 million.

Depression, Addiction, Clinics and More

This has already been a big year for psychedelics, with no signs that momentum will begin to wane anytime soon given the uptick in research. In addition to Tryp, a small group of companies are distinguishing themselves as pioneers in the space.

Seelos Therapeutics Inc. (NASDAQ: SEEL) is a member of the Defiance Next Gen Altered Experience ETF, the first U.S.-listed Exchange Traded Fund focused on psychedelics. The company has a diverse pipeline that includes non-psychedelic assets but earned its spot in the ETF for its lead program of SLS-002 (intranasal racemic ketamine), which recently released positive top-line data from Part 1, the open-label cohort, of its potentially registrational Proof-of-Concept study for acute suicidal ideation and behavior in patients with major depressive disorder (“MDD”).

Awakn Life Sciences Corp. (NEO: AWKN) has a multiprong business strategy, including clinical operations and research into developing a pipeline of next-generation therapeutics to treat addiction with a near-term focus on ketamine, a medium-term focus on MDMA, and a long-term focus on Awakn’s own developed drugs. This month, Awakn said it will undertake a program of clinical research designed to demonstrate the effectiveness for ketamine-assisted psychotherapy against multiple addictions, including alcohol use disorder (“AUD”) and gambling addiction.

Field Trip Health Ltd. (TSX: FTRP) (OTCQX: FTRPF) is known as a global leader in the development and delivery of psychedelic therapies. The company’s Field Trip Discovery division develops psychedelic molecules and conducts advanced research on plant-based psychedelics, while the Field Trip Health division builds centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools to facilitate scaling.

Small Pharma Inc. (TSX.V: DMT) is a neuropharmaceutical company focused on psychedelic-assisted N,N-dimethyltryptamine (“DMT”) therapies. Small Pharma is planning to initiate a Phase 2a trial to evaluate its SPL026 product for depression by the end of the year and has launched a training program to educate psychologists on the process required for the support and completion of Small Pharma’s DMT-assisted therapy clinical trials.

Like any emerging market, psychedelic stocks have certainly had their ebbs and flows of attention and excitement. We are now beginning to see more separation among the field of psychedelic participants as speculation gives way to more fundamental analysis of the companies’ drug development pipelines and the unique indications they are pursuing.  And we are just scratching the surface with understanding the medical potential of psychedelic medicines for the millions of patients who need them most.

For more information about Tryp Therapeutics, please visit Tryp Therapeutics Inc.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Friendable, Inc. (FDBL), Its Technology, Innovation, and Commitment to Artists

  • The single biggest slice of an artists’ earnings (28%) comes from touring, meaning live performances, and, with the pandemic, artists were restricted in doing live shows
  • Friendable addresses this with its Fan Pass platform, allowing artists to make money from virtual events, video content views, artist contests, merchandise sales, and even ticket sales
  • Friendable continues to innovate and leverage technology to address the new challenges that artists face

As of early 2020, touring, shows, and live performances accounted for much of an artists’ earnings, at 28%. This was closely followed by teaching at 22%, salaries at 19%, session playing at 10%, and then composing and songwriting at 6% (https://nnw.fm/rb41l).

With the growing challenges associated with live performances and shows, artists are exploring new ways to deliver the same experience to their audience and make money from it. Virtual experiences prove to be more appealing to artists given how well they have taken up different social media platforms and their websites.

So far, numerous platforms have presented a compelling value proposition for artists and how they can make money. However, very few stand out as much as Fan Pass does.

Friendable (OTC: FDBL) is a mobile technology marketing company focused on developing and identifying products, services and brand opportunities with mass market potential and scalability. Friendable has since removed the social dating app from the app stores and has pivoted its business focus to Fan Pass, the livestream artist platform. Launched July 24, 2020, the Fan Pass livestream platform has proven to be invaluable for artists and fans alike as performances shifted from the stage to the screen (https://nnw.fm/JMXjl).

At the core of Friendable’s Fan Pass platform, the company is committed to connecting fans to their favorite artist. Doing so allows the artist to make money from their art and brand. More importantly, they do this virtually and while breaking the mold of the traditional music industry.

In April 2021, Friendable announced that it would offer Non-fungible Tokens (“NFTs”), a unique addition to its product and service offering (https://nnw.fm/nsBQO). Each NFT offered would represent a unique opportunity for the artist and any other parties involved to monetize and seek other opportunities with brand sponsors and retail brands.

The NFT addition allows artists to increase their value through multiple limited-edition releases dependent on availability and exclusivity. This means fans can enjoy exclusive privileges such as access to the artist or limited-edition merchandise, while the artist can make money from their art and their brand.

As of July 2021, Friendable had over 5,000 Fan Pass artist sign-ups, a massive milestone for the company (https://nnw.fm/naJU1). Additionally, on July 24, 2021, the company submitted its Fan Pass version 2.0 Livestream artist platform to the Apple App and Google Play Stores, which shows its commitment to innovation and the use of technology to appeal more to artists. Even as these signify the company’s growth, they also show that artists appreciate the value that Friendable is offering and the opportunities it presents for their revenue and overall brand growth.

As time progresses, Friendable continues to strengthen its commitment to further innovating and building its product line, thereby bringing even more value to the audience and, most importantly, the artists. The company also continues to leverage technology to achieve this and has made incredible achievements so far. It continues to prioritize the artist as it seeks to address the new challenges they continue to face as time progresses.

For more information, visit the company’s website at www.Friendable.com.

NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://nnw.fm/FDBL

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

RYAH Group Inc. (CSE: RYAH) Globally Unlocking Data in the Complete Therapeutic Plant Lifecycle

  • Providing a holistic approach to therapeutic plant treatment by unlocking data from seed to consumption
  • RYAH Group is providing needed dosing devices globally to drive innovation and deliver cutting edge plant-based medical solutions globally 
  • With over 200k registered users, RYAH Group is one of the largest plant-based medicine databases in the world and regularly releases and shares valuable insights collected

RYAH Group (CSE: RYAH), formerly RYAH Medtech, is leading the way forward by providing a holistic approach to therapeutic plant treatment by unlocking the data in the complete plant lifecycle (seed to consumption). Known for its high-quality information and digital health care analytics, RYAH Group is positively impacting the future treatment of patients for various medical conditions worldwide. The Company has globally expanded its reach in IoT hardware, software, and data analytics making it possible for researchers to significantly reduce variations in patient-related trials. 

Whether combining forces with the University of Milan to rigorously map out the behavior of cannabis strains to create accurate milligram dosing (https://nnw.fm/JY9DX), providing the necessary dose-measuring devices to an oncology clinic in the UK for the largest of its kind cannabis clinical trial (https://nnw.fm/ZUAU6), or partnering with companies like Medical Kiwi to drive innovation and deliver cutting edge plant-based medical solutions in New Zealand (https://nnw.fm/Kmlx1) – RYAH Group is paving the way for a better understanding and better outcomes of plant-based treatments globally.

This is achieved by having multiple touch points and working with multiple players throughout the plant’s lifecycle. The Company has partnered with growers, dispensaries, clinical trials, researchers, and patients to collect seed-to-consumption data. This creates a deeper understanding of the roles of formulations and dosing in treatments.

In order to collect the data, RYAH Group has created smart devices combined with artificial intelligence and an integrated platform that allow both the patient and doctor to regulate prescriptions safely and seamlessly. The HIPAA-compliant patient data is monitored by an AI platform throughout the patient’s session and formulation lifecycle providing additional data that is fed into the Cloud that continues the process. 

The Company’s smart devices include: 

  • RYAH Smart Patch – used primarily by physical therapists and cannabis-treated patients, pain relief professionals and occupational therapists for site-specific therapy to treat a variety of conditions
  • RYAH Dry-herb Inhaler – measures inhalations to deliver precise and predictable results
  • RYAH Pen – oral drug dispenser connected to a mobile application, allows users to track dosing and usage statistics
  • RYAH MD – platform for doctors to remotely monitor and control their patients’ dosing regimen with RYAH’s suite of dose measuring products

RYAH Group uses a data-driven approach that combines dosing data, lab test information, and consumer feedback. Big data and AI are used to discover breakthroughs and better enable providers to create highly personalized dosing regimens for the end users. With over 200k registered users, RYAH Group is one of the largest plant-based medicine databases in the world and regularly releases and shares valuable insights collected. These data reports are released monthly and available to everyone at www.RYAHGroup.com/news

In the U.S., study has been limited for the last 50 years due to federal regulations. But change is on the horizon (https://nnw.fm/fZ6XW). Researchers in the U.S., currently restricted to federally cultivated cannabis, will soon have access to the therapeutic plants and products that end users are actually using. Cannabis research in 2022 will be conducted in a way that will benefit the consumer and lead to better medicinal products and safer recommendations. RYAH is ready and has the necessary IoT devices needed to ensure these future studies collect and analyze the data in the most effective way possible.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://nnw.fm/RYAH

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Is ‘One to Watch’

  • MINDCURE’s proprietary digital therapeutics technology platform creates a high barrier to entry for any potential competitors
  • The company maintains active partnerships with growing firms in AI, technology, and mental health
  • MINDCURE’s world-class scientific discovery team has decades of combined experience in researching and commercializing pharmaceutical grade drugs
  • The company has demonstrated a clear path to near-term revenues and boasts a strong financial position

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”) is a diversified life sciences company at the forefront of the mental health industry. The company is currently developing digital therapeutics and researching psychedelic compounds, while innovating and commercializing new ways to promote healing and improve mental health.

MINDCURE’s research and digital therapeutics technology supports access to safe, science-based, evidence-backed psychedelic-assisted therapies globally. With hundreds of millions of people suffering from mental illnesses worldwide and an estimated $1 trillion in lost productivity per year, psychedelics offer promising alternatives for healing. This medical need has been amplified by the COVID-19 pandemic. According to the Centers for Disease Control and Prevention, 40 percent of U.S. adults reported struggling with substance abuse or mental health issues during the pandemic.

MINDCURE is uniquely positioned to address these medical needs. By concentrating on both technology and research, the company is focusing on near-term revenue generation, targeting a longer-term, blue sky horizon and hedging against regulatory unknowns with a scalable, adaptive model. MINDCURE’s software-as-a-service (SaaS) platform, iSTRYM, scales globally and services every psychedelic medicine without the capital-intensive drag of clinic scale-out costs. The company plans to first enter the market for psychedelic-assisted psychotherapy, then to move into the larger fields of technologically undisrupted psychotherapy and psychiatry.

Technology

Digital therapeutics include health interventions delivered through a smart device to induce a behavioral change in the patient. The global market is focused on simplifying behavioral change and empowering consumers to take charge of their own health. iSTRYM is the company’s AI-driven software platform that enables personalized and quantified outcomes in psychedelic therapy. The SaaS platform modernizes care, taking it from manual to digital and bringing better treatment outcomes for patients and therapists while lowering costs for insurers.

iSTRYM offers clinicians direct access to global, science-backed, evidence-based protocols, integration plans, insights into client journeys, and real-time assessments for personalized care. Patients access the platform on their smart devices, enjoying transparency into their wellness journeys, personalized care resources, and optimized relationships with their practitioners. The minimal viable product (“MVP”) of the software is being launched in Q3 2021. MINDCURE targets a Q1-Q2 2022 commercial product launch.

Research

In June 2021, the company announced it had completed the first stage of manufacturing pharmaceutical-grade synthetic ibogaine to be used in clinical research. In July, MINDCURE announced it had filed U.S. Provisional Patent applications for the company’s first full synthetic routes to create ibogaine. The company’s pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug.

The company is also actively researching ibogaine as a potential treatment for Traumatic Brain Injury and related conditions. Preliminary data show the drug may also have promise as a treatment for neuropathic pain and migraines. In addition, research indicates ibogaine may help repair and rewire the brain’s neural pathways, making it potentially useful in the treatment of addictions.

Market Outlook

MINDCURE actively develops technology, conducts research, and distributes products in several market spaces. The global market for digital therapeutics is projected to grow to $6.9 billion by 2025, from an estimated $2.1 billion in 2020. In North American alone, the market is forecast to reach $5 billion by 2025.

The market for treatment of drug, alcohol and other addictions is estimated to be worth $38.2 billion in 2021, with a forecast CAGR of 5.2 percent for the next several years. The global market for the treatment of neuropathic pain is forecast to account for $9 billion by 2027, while drug treatment for migraines is expected to have a value of $2.1 billion by 2025.

Management Team

Kelsey Ramsden is President and CEO of MINDCURE. She has 15 years of experience founding, scaling, and operating innovative companies across Canada and the Caribbean. She has built multiple eight-figure businesses and twice been named Canada’s Top Female Entrepreneur. She holds a seat on the Entrepreneurship Council for the University of Western Ontario, where she is also a faculty member. She has an MBA from the Richard Ivey School of Business at the University of Western Ontario.

Dr. Joel Raskin is the Chief Medical Officer at MINDCURE. He is a psychiatrist and academic with 20 years international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch and commercialization with Eli Lilly & Co., where, as Senior Director, he led the medical affairs team for Alzheimer’s disease diagnostics and therapeutics. He earned his medical degree from the University of Toronto and is a Fellow of the Royal College of Physicians and Surgeons of Canada in Psychiatry.

Tarik Lebbadi is the COO at MINDCURE. He has more than 13 years of international operational experience. Before joining the company, he led the medical division of Johnson & Johnson in Morocco. He holds a BA in mathematics and computer science from Ripon College and an MBA from IESE Business School in Barcelona, Spain.

Geoff Belair is the CTO at MINDCURE. He has 30 years of experience working in highly regulated industries, including fintech and banking. He was the senior architect and creator of the Integration Services Team at banking solutions company Fincentric Corporation. Before joining MINDCURE he was Vice President of Information Technology at Westland Insurance.

Michael Wolfe, CPA CA, is MINDCURE’s CFO. He has 30 years of experience in finance, accounting, private equity, and business valuation. He was previously CFO of Baylin Technologies Inc., as well as CFO of several mid-market Canadian companies, including Masstech Group Inc. He was General Partner at VenGrowth Capital Partners Inc. He holds an MBA from McMaster University and a BA in business and economics from the University of Western Ontario.

Daniel Herrera is Vice President of Growth & Strategic Partnerships at MINDCURE. He is a former pharmaceutical executive with extensive experience in highly regulated industries. He is experienced with medical affairs, product development and product licensing, negotiations with public and private payers, GPOs, and pharmacy buyers, as well as strategic partnerships resulting in high-value M&A transactions. He is a graduate of McGill University and the University of Montreal and holds an MBA from the John Molson School of Business at Concordia University.

For more information, visit the company’s website at www.MindCure.com.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at https://nnw.fm/MCURF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Heavy Hurricane Forecast Portends Busy Season for Sustainable Green Team Ltd. (SGTM)

  • Some estimate the U.S. will run out of landfill space within 15 years
  • This year’s hurricane season expected to have above average activity
  • SGTM, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging, sales

This month, the world watched as Hurricane Elsa made landfall in Cuba on July 5, tore through Jacksonville, Florida days later and then proceed to wreak havoc up the East Coast and into Atlantic Canada (https://nnw.fm/uPNqu). Indeed, the latest iteration of hurricane season is upon us, and it’s expected to be an above average year for activity, which has cities scrambling to fill public works jobs and Sustainable Green Team (OTC: SGTM) readying its crews for months of debris removal (https://nnw.fm/CyOXY).

Officially, the Atlantic hurricane season, which covers the Atlantic Ocean, Gulf of Mexico and the Caribbean Sea, runs from June 1 – November 30. By definition, Elsa, the first of the year, was only a Category 1 hurricane, but it certainly demonstrated the raw power of torrential winds and rain that downed countless trees and left over 100,000 without power in its wake, including over 85,000 in New Jersey alone (https://nnw.fm/kv8rk).

Sustainable Green Team, Ltd., through its subsidiaries, including National Storm Recovery LLC, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The Delaware-based company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation.

To understand the importance of Sustainable Green Team’s work, consider that SWEEP (Solid Waste Environmental Excellence Performance) contests that the U.S. is charting a course to run out of landfill space in the next 15 years (https://nnw.fm/5L40t). Environmentalists also warn that uncaptured methane gas from landfills was the third biggest contributor to human-related methane emissions in the U.S. in 2018, with the equivalency to carbon dioxide emissions from 20.6 million passenger vehicles driven for one year (https://nnw.fm/wACu1).

Sustainable Green Team’s solutions are rooted in sustainability and based on vertically integrated operations. In the event of a storm, SGTM’s team is deployed from a mobile command center to designated sites to strategize with national partners comprised of government agencies, prime contractors, and subcontractors.

Next, its tree services division and fleet of trucks and machinery cut and gather tree debris for collection sites. From there, the processing division takes over, using the tree debris as feedstock that is turned into a variety of organic, next-generation mulch products that are subsequently sold to landscapers, installers and garden centers.

In short, a downed tree isn’t used for another layer in a landfill; it’s recycled into a premium product for SGTM’s municipal, commercial, and residential customers. Better still, it helps in the efforts to prevent deforestation.

The company is far removed from a typical OTC company. It has six different production facilities covering hundreds of acres in Florida and Georgia. It also has seven co-packing partners, 23 distribution centers, eight intermodal ramps, and direct contracts with CSX and Norfolk Southern to move product by rail. In 2020, SGTM acquired Ohio-based Mulch Manufacturing, widening its national footprint and adding contracts for bagged mulch with big box stores to its revenue stream.

To that point, SGTM has parlayed it environmentally friendly processes into growing sales. The Company reported record revenue of $9.29 million, $1.4 million in gross profit and $41.48 million in total assets for the quarter ended April 30, 2021.

No one likes to hear about a hurricane or the see the devastation one leaves behind. Unfortunately, it makes for good news reports for a few days, but then the cameras disappear, and communities are left to pick up the pieces. Thankfully, a company like SGTM is there with the complete infrastructure to assist in the eco-friendly manner to see that the environmental damage doesn’t have to be any more than it already is.

For more information on Sustainable Green Team Management, visit www.CentralFloridaArborcare.com.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://nnw.fm/SGTM

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.